EdgePoint Investment Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

EdgePoint Investment Group’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,674,185	Closed	-$2.57M	–	43
2019 Q4	$2.57M	Buy	3,674,185 +573,254	+18%	+$405K	0.02%	36
2019 Q3	$2.25M	Buy	3,100,931 +269,376	+10%	+$195K	0.02%	36
2019 Q2	$2.21M	Buy	2,831,555 +410,296	+17%	+$456K	0.02%	36
2019 Q1	$2.98M	Buy	2,421,259 +52,440	+2%	+$59.7K	0.03%	38
2018 Q4	$1.99M	Buy	2,368,819 +173,756	+8%	+$196K	0.02%	39
2018 Q3	$6.5M	Hold	2,195,063	–	–	0.07%	41
2018 Q2	$8.08M	Hold	2,195,063	–	–	0.1%	39
2018 Q1	$7.68M	Buy	2,195,063 +3,150	+0.1%	+$13.4K	0.11%	39
2017 Q4	$6.84M	Buy	2,191,913 +1,153,347	+111%	+$5.54M	0.1%	39
2017 Q3	$7.3M	Buy	+1,038,566	New	+$8.32M	0.11%	41

EdgePoint Investment Group's NVLN Position: Q1 2020 in Review

EdgePoint Investment Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2020, closing a stake of 3,674,185 shares — an estimated $2.57M sold.

EdgePoint Investment Group first reported a position in NVLN in Q3 2017 and held it in 10 quarters. The position peaked at $8.08M in Q2 2018. 1 fund tracked by Wall St. Rank holds NVLN as of Q1 2020.

EdgePoint Investment Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2020 after selling out during the quarter.
EdgePoint Investment Group sold 3,674,185 Novelion Therapeutics Inc. Common Shares shares in Q1 2020, an estimated $2.57M.
EdgePoint Investment Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q3 2017 and held it in 10 quarters.
EdgePoint Investment Group's Novelion Therapeutics Inc. Common Shares position peaked at $8.08M in Q2 2018.
1 fund tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2020.

Based on EdgePoint Investment Group's 13F filing for Q1 2020, filed 4 May 2020.